Stock IMCR IMMUNOCORE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Immunocore Holdings plc

Equities

IMCR

US45258D1054

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
59.46 USD +0.69% Intraday chart for Immunocore Holdings plc +2.52% -12.97%
04-29 Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target MT
03-21 Immunocore Holdings Files Mixed-Securities Shelf Registration MT

Business Summary

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Number of employees: 497

Sales per Business

USD in Million2022Weight2023Weight Delta
T-Cell Receptors Bispecific Immunotherapies
100.0 %
177 100.0 % 310 100.0 % +75.12%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
72.4 %
132 74.7 % 224 72.4 % +69.62%
Europe
27.1 %
44 24.7 % 84 27.1 % +92.30%
International
0.5 %
1 0.6 % 2 0.5 % +52.47%

Managers

Managers TitleAgeSince
Bahija Jallal CEO
 Chief Executive Officer 62 18-12-31
Brian DiDonato DFI
 Director of Finance/CFO 57 20-03-31
John Trainer COO
 Chief Operating Officer 50 23-09-30
Mohammed Dar CTO
 Chief Tech/Sci/R&D Officer - 19-03-31
David Berman CTO
 Chief Tech/Sci/R&D Officer - 18-12-31
Lily Hepworth LAW
 General Counsel - 18-08-31
Ralph Torbay PRN
 Corporate Officer/Principal - 21-02-15
Tina St. Leger HRO
 Human Resources Officer 56 22-02-02
John Goll AUD
 Comptroller/Controller/Auditor - 23-07-31

Members of the board

Members of the board TitleAgeSince
Robert Perez BRD
 Director/Board Member 59 19-08-31
John Bell CHM
 Chairman 71 15-02-28
Bahija Jallal CEO
 Chief Executive Officer 62 18-12-31
Peter Ratcliffe BRD
 Director/Board Member 69 -
Kristine Peterson BRD
 Director/Board Member 64 17-10-31
Roy Herbst BRD
 Director/Board Member 60 21-01-27
Travis Coy BRD
 Director/Board Member - 19-08-31
Siddharth Kaul BRD
 Director/Board Member - 22-06-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,714,650 0 0 45.60 %
Stock B 1 48,010,999 44,126,909 ( 91.91 %) 0
Stock C 1 47,041,372 0 0

Shareholders

NameEquities%Valuation
RTW Investments LP
12.24 %
6,096,387 12.24 % 396 M $
Wellington Management Co. LLP
11.04 %
5,498,677 11.04 % 357 M $
Wellington Management Co. LLP
8.656 %
4,312,611 8.656 % 280 M $
T Rowe Price Associates, Inc. (13F Subfiler)
5.910 %
2,944,574 5.910 % 191 M $
Rock Springs Capital Management LP
5.342 %
2,661,507 5.342 % 173 M $
Baker Bros. Advisors LP
5.060 %
2,520,731 5.060 % 164 M $
Fidelity Management & Research Co. LLC
3.405 %
1,696,386 3.405 % 110 M $
Baker Bros. Advisors LP
3.042 %
1,515,318 3.042 % 98 M $
Paradigm BioCapital Advisors LP
2.918 %
1,453,883 2.918 % 95 M $
Bellevue Asset Management AG
1.959 %
976,054 1.959 % 63 M $
NameEquities%Valuation
ELI LILLY AND COMPANY
6.254 %
2,548,145 6.254 % 166 M $
General Atlantic LLC
4.290 %
1,747,849 4.290 % 114 M $
Baker Bros. Advisors LP
2.301 %
937,553 2.301 % 61 M $
Brian DiDonato
0.0472 %
19,230 0.0472 % 1 M $
John Bell
0.0330 %
13,452 0.0330 % 874 380 $
Peter Ratcliffe
0.000817 %
333 0.000817 % 21 645 $
Tina St. Leger
0.000000 %
0 0.000000 % - $
Kristine Peterson
0.000000 %
0 0.000000 % - $
Siddharth Kaul
0.000000 %
0 0.000000 % - $
Roy Herbst
0.000000 %
0 0.000000 % - $

Company contact information

Immunocore Holdings Plc

92 Park Drive Milton Park

OX14 4RY, Abingdon

+44 12 3543 8600

http://www.immunocore.com
address Immunocore Holdings plc(IMCR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Immunocore Holdings plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
47.28 GBP
Average target price
66.95 GBP
Spread / Average Target
+41.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
IMMUNOCORE HOLDINGS PLC Stock Immunocore Holdings plc
-12.97% 2.98B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IMCR Stock
  4. Company Immunocore Holdings plc